Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4515-4517

  Wundrack, I ^a   Sasiadek, M ^b   Blin, N ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alleles; Brain tumor; Chromosome 22; Detoxification gene; Mutation

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE;

ADULT; ARTICLE; BLOOD; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; NEUROFIBROMATOSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALLELES; CYTOCHROME P-450 CYP2D6; EXONS; FEMALE; GENES, RECESSIVE; HUMANS; INTRONS; LEUKEMIA; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PARKINSON DISEASE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEQUENCE DELETION;

EID: 0031409307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Neber D, Gonzales F: P450 genes: structure, evolution, regulation. Ann Rey Biochem 56: 945-993, 1987.
2. Crespi C, Penman B, Gelboin El, Gonzales F: A tobacco smoke-derived nitrosamine is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12: 1197-1201, 1991.
3. Neber D: Growth signal pathways. Nature 347: 709-710, 1990.
4. Gough A, Miles J, Spurr N, Moss J, Gaedigk A, Eichelbaum M, Wolf C: Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347: 773-776, 1990.
5. Smith C, Gough A, Leigh P, Summers B, Harding A, Maraganore D, Sturman S, Schapira A, Williams A, Spurr N, Wolf C: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339: 1375-1377, 1992.
6. Broly F, Marez D, LoGuidice J, Sabbagh N, Legrand M, Boone P, Meyer U: A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 96: 601-603, 1995.
7. Guengerich FP: Polymorphism of cytochrome P450 enzymes. Anaesth Pharmacol Rev 1: 325-329, 1993.
8. Ayesh R, Idle J, Ritchie J, Crothers M, Hetzel M: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170, 1984.
9. Hirvonen A, Husgafel-Pursiainen K, Anttila S, Karjalainen A, Vainio H: Polymorphism in CYP1A1 and CYP2D6 genes. Environ. Health Perspect 101: 109-112, 1993.
10. Wolf C, Smith C, Gough A, Moss J, Vallis K, Howard G, Carey F, Mills K, McNee W, Carmichael J, Spurr N: Relationship between the debrisoqine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035-1038, 1992.
11. Wundrack I, Meese E, Mullenbach R, Blin N: Debrisoquine hydroxylase gene polymorphism in meningioma. Acta Neuropathol 88: 472-474, 1994.
12. Elexpuru CJ, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, Broome J, Jones P, Inskip A, Alldersea J, Fryer AA, Strange R: Susceptibility to astrocytoma and meningioma. Cancer Res 55: 4237-4239, 1995.
13. Wundrack I, Kluwe L, Kehrer H, Mautner V, Jagielski J, Krone W, Blin N. (1997) Incresased P450 CYP2D6 mutation rate in 22q13 reducing detoxification metabolism in neurofibromatosis 2. Submitted.